➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Last Updated: September 17, 2021

DrugPatentWatch Database Preview

Details for Patent: 7,803,839

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,803,839 protect, and when does it expire?

Patent 7,803,839 protects COTELLIC and is included in one NDA.

This patent has sixty-two patent family members in thirty-one countries.

Summary for Patent: 7,803,839
Title:Azetidines as MEK inhibitors for the treatment of proliferative diseases
Abstract: Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.
Inventor(s): Aay; Naing (San Mateo, CA), Anand; Neel Kumar (Burlingame, CA), Blazey; Charles M. (San Francisco, CA), Bowles; Owen Joseph (Pacifica, CA), Bussenius; Joerg (Foster City, CA), Costanzo; Simona (Los Altos, CA), Curtis; Jeffry Kimo (San Anselmo, CA), DeFina; Steven Charles (Burlingame, CA), Dubenko; Larisa (San Francisco, CA), Joshi; Anagha Abhijit (Fremont, CA), Kennedy; Abigail R. (Oakland, CA), Kim; Angie Inyoung (San Mateo, CA), Koltun; Elena S. (Foster City, CA), Manalo; Jean-Claire Limun (Daly City, CA), Peto; Csaba J. (Alameda, CA), Rice; Kenneth D. (San Rafael, CA), Tsang; Tsze H. (El Cerrito, CA)
Assignee: Exelixis, Inc. (South San Francisco, CA)
Application Number:11/995,928
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,803,839

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Genentech Inc COTELLIC cobimetinib fumarate TABLET;ORAL 206192-001 Nov 10, 2015 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,803,839

PCT Information
PCT FiledOctober 05, 2006PCT Application Number:PCT/US2006/039126
PCT Publication Date:April 19, 2007PCT Publication Number: WO2007/044515

International Family Members for US Patent 7,803,839

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 504565 ⤷  Try it Free
Australia 2006302415 ⤷  Try it Free
Brazil PI0617165 ⤷  Try it Free
Canada 2622755 ⤷  Try it Free
Canada 2927656 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.